

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
148739	16/SC/0071	195573	A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma	No		51			14/02/2017	17/10/2018		11/09/2018	07/12/2018	Please Select...		D - Sponsor Delays	Awaiting Green Light from Sponsor	Sponsor
148740	18/NW/0645	249859	A randomized, controlled trial to evaluate impact of energy expenditure information from indirect calorimeter on the outcome of weight loss during a standardised multicomponent weight management intervention in non-diabetic & pre-diabetic obese subjects	Yes	28/01/2019	50	61	111	29/03/2018	09/10/2018	09/11/2018	20/11/2018	28/11/2018	Please Select...	28/11/2018			Please Select...
148741	18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	No		0			25/06/2018	05/10/2018	26/04/2018	20/09/2018	05/10/2018	Please Select...		D - Sponsor Delays	Sponsor delay due to sponsor electronic system	Sponsor
148742	18/WA/0154	233884	WHITE 8 COPAL: A Randomised Controlled Trial of low dose single antibiotic loaded cement versus high dose dual antibiotic loaded cement in patients receiving a hip hemiarthroplasty after fracture.	Yes	10/12/2018	0	6	6	13/08/2018	04/12/2018	10/05/2018	27/11/2018	04/12/2018	Please Select...	06/12/2018			Please Select...
148743	18/SS/0033	242190	A randomised, double-blind placebo controlled trial of the effectiveness of the	Yes	09/11/2018	3	21	24	16/08/2018	16/10/2018	09/08/2018	12/10/2018	19/10/2018	Please Select...	19/10/2018			Please Select...

			beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease.															
148744	17/NW/0352	226135	A randomised controlled trial of the effectiveness, and cost-effectiveness, of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for trauma.	No		10			18/07/2017	11/02/2019	18/08/2017	14/01/2019	21/02/2019	Please Select...		D - Sponsor Delays	awaiting green light from Sponsor	Sponsor
148745	18/NW/0296	248487	Carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE)	No		4			04/12/2018	21/02/2019	19/10/2018	21/02/2019	25/02/2019	Please Select...	25/02/2019	F - No patients seen	patients seen and consented but failed screening process for randomisation	Neither
148746	18/NI/0129	218623	Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients	No		0			14/06/2018	11/02/2019	17/10/2018	08/02/2019	11/02/2019	Please Select...	11/02/2019	E - Staff availability issues	staffing issues within specialty	NHS Provider
148747	18/EE/0399	253572	A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sclerosis	No		0			17/12/2018	20/03/2019	14/01/2019	13/03/2019	20/03/2019	Please Select...	20/03/2019			Please Select...
148748	16/NE/0140	199321	1 EMT2: EPA for Metastasis Trial 2 A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases	No		0			05/10/2018	14/03/2019	12/01/2018	08/03/2019	14/03/2019	Please Select...	21/03/2019			Please Select...
148749	18/EM/0364	254750	NN9838-4433 - Investigation of safety and efficacy	Yes	01/03/2019	60	17	77	14/12/2018	14/12/2018	10/01/2019	05/02/2019	12/02/2019	Please Select...	12/02/2019			Please Select...

			of NNC0174-0833 for weight management – a dose finding trial															
148750	18/LO/0745	231612	IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	No		93			16/11/2018	18/11/2018	11/02/2018	14/02/2019	19/02/2019	Please Select...	25/02/2019	F - No patients seen	2 patients have screen failed	Neither
148751	18/EE/0153	223791	SALivary electrostimulation for the treatment of dry mouth in patients with Sjögren's syndrome: a multicentRe randomISEd sham-controlled double-blind study	Yes	10/04/2019	0	58	58	20/11/2018	11/02/2019	16/07/2018	07/02/2019	11/02/2019	Please Select...	18/02/2019			Please Select...
148752	18/LO/1258	248312	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG0011 in Patients With Idiopathic Pulmonary Fibrosis - BIOGEN	Yes	21/06/2019	0	59	59	03/07/2018	23/04/2019	18/09/2018	10/04/2019	23/04/2019	Please Select...	14/05/2019			Please Select...
148753	18/EM/0229	250101	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY - PROTECT	No		14			06/03/2019	30/04/2019	04/10/2018	01/05/2019	14/05/2019	Please Select...		D - Sponsor Delays	Trust still awaiting green light from Sponsor	Sponsor
148754	19/SC/0034	254823	A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. GALAPAGOS	Yes	10/07/2019	107	56	163	20/10/2018	28/01/2019	29/04/2019	10/05/2019	15/05/2019	Please Select...	03/06/2019			Please Select...
148755	17/NE/0027	215796	CRest 2 - Colorectal Endoscopic Stenting Trial 2	No		0			23/10/2018	06/06/2019	03/04/2017	03/05/2019	06/06/2019	Please Select...		D - Sponsor Delays	Trust still awaiting Sponsor Green Light	Sponsor
148759	18/NW/0180	236218	Sodium Valproate for Epigenetic	No		246			09/07/2018	26/11/2018	03/09/2018	25/07/2019	30/07/2019	Please Select...		D - Sponsor	Trust still awaiting	Sponsor

			Reprogramming in the Management of High Risk Oral Epithelial Dysplasia - SAVER												Delays	Sponsor Green Light		
148760	19/SC/0122	259342	A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi Syndrome	No		153			08/03/2019	08/03/2019	07/05/2019	05/08/2019	08/08/2019	Please Select...	15/08/2019	F - No patients seen	Patient Screen Failure	Neither
148761	19/NW/0363	250571	Protocol I4V-MC-JAJA (RA-BRIDGE) Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis	No		0			29/05/2019	20/08/2019	08/08/2019	16/08/2019	20/08/2019	Please Select...	27/08/2019	F - No patients seen		Neither
148762	19/SC/0309	264959	A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis	Yes	10/10/2019	84	27	111	21/06/2019	21/06/2019	20/08/2019	12/09/2019	13/09/2019	Please Select...	30/09/2019	J - Other	This is an extension study, and patients are not eligible for entry until October 2019	Neither
148763	16/ES/0110	207747	Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid	No		165			04/04/2019	04/04/2019	12/01/2017	04/09/2019	16/09/2019	Please Select...		D - Sponsor Delays	Trust still awaiting green light from Sponsor	Sponsor